Molecular Partners reports Phase II data for MP0250 in MM

Molecular Partners AG (SIX:MOLN) reported data from seven evaluable patients with relapsed and refractory multiple myeloma (MM) in a Phase II trial showing that 8 mg/kg IV MP0250 every three weeks in combination with Velcade bortezomib and dexamethasone led to three partial response and one minimal response. No dose-limiting toxicities (DLTs) were reported. Additional data are expected by year end.

The two-part, open-label, European trial is expected to enroll 12 patients in the dose-escalation Part 1 and 28 patients in the dose-expansion Part 2. The primary endpoint is overall response rate (ORR). Secondary endpoints include safety, immunogenicity, progression-free survival (PFS) and duration of response...